Business Wire

New CSC Research Finds Over 90% of Websites Linked to Donald Trump and Joe Biden Campaigns at Risk for Potential Redirection, Disinformation, and Data Theft

8.10.2020 13:00:00 EEST | Business Wire | Press release

Share

CSC, a world leader in business, legal, tax, and domain security, today released new research from their Digital Brand Services (DBS) division that reveals areas of risk for prominent election-related websites. The research indicates that web domains closely linked to the campaign websites for Joe Biden and Donald Trump lack basic domain security protocols and are being targeted for disinformation activities such as domain spoofing, and threats including domain name and domain name system (DNS) hijacking, and phishing.

On the heels of its recent Forbes Global 2000 research, CSC is seeing major risks related to the manipulation of web properties that voters rely on for information and donations. Findings show that over 90% of these web properties are not using registry locks to protect their domains from domain and DNS hijacking that can lead to phishing attacks, network breaches, and email compromise.

“As noted in our previous research, we’ve consistently seen domains emerge as a threat vector for enterprises, and an area that is continuously overlooked in cyber security. Due to the sensitivity and importance of the U.S. election process, domain security remains a major vulnerability for the potential of foreign interference, fraud, and misinformation,” says Mark Calandra, executive vice president for CSC DBS. “As an organization with the most visibility into the domain landscape, we advocate for the sanctity of voter trust and encourage both presidential candidates and other websites in the electoral ecosystem to prioritize domain security on their websites to ensure security and build confidence.”

"We have reached the point where awareness is not enough. Those responsible for managing domain registrations, including registrars and hosting companies, need to have an actionable plan that is aligned with best practices. Additionally, experiences must be shared between those within the industry for the good of the wider internet community," said Matthew Stith, industry liaison at Spamhaus. “Without this commitment, users will be open to continued manipulation and fraud."

In April of 2020 when domain names were at the center of many COVID-19 related fraud schemes, Senators Mazie K. Hirono (D-Hawaii), Cory Booker (D-N.J.), and Maggie Hassan (D-N.H.) called on domain name registrars and hosting sites to combat scams and misinformation. CSC’s research shows that domain security and preventing domain spoofing continue to be an oversight even with top election-related web properties. Our research shows that more than 75% of these election-related domains are using retail-grade domain registrars, which do not provide advanced security protocols.

Our research also showed that, of the typo domains related to joebiden.com and donaldjtrump.com, 60% are still available for registration, thereby posing future threats. Additionally, more than a third of those presidential candidate typo domains are linked to third parties; of that one third, nearly 70%:

  • Are configured to send and receive emails, which can be used to lure donors to phishing sites
  • Were registered in 2020 leading up to the November election
  • Disguise the owner’s identity behind proxy or privacy services

With cyber criminals subverting activities on these websites to disseminate misinformation or commit fraud against web visitors, there is also the threat of ransomware. Simon Chassar, chief revenue officer at NTT Ltd.’s Security division states, "NTT's September Monthly Threat Report identified ransomware as a significant threat to the U.S. election infrastructure. With DNS, domains, and email being a potential vehicle to distribute malicious content, our NTT Ltd. Security division suggests focus in this area, ensuring it is secure by design."

For additional details on these findings, visit the CSC blog “U.S. Election-Related Web Properties Prone to Fraud and Misinformation Due to Lack of Domain Security.”

Note: CSC aggregated this data using SimilarWeb.com for the period of August 1 – August 30, 2020.

About CSC

CSC is the trusted provider of choice for the Forbes Global 2000 and the 100 Best Global Brands® in enterprise domain names, domain name system (DNS), digital certificate management, as well as digital brand and fraud protection. As global companies make significant investments in their security posture, CSC can help them understand known security blind spots that exist and help them secure their digital assets. By leveraging CSC’s proprietary solutions, companies can get secure to protect against cyber threats to their online assets, helping them avoid devastating revenue loss, brand reputation damage, or significant financial penalties because of policies like the General Data Protection Regulation (GDPR). CSC also provides online brand protection—the combination of online brand monitoring and enforcement activities—taking a holistic approach to digital asset protection, along with fraud protection services to combat phishing. Headquartered in Wilmington, Delaware, USA, since 1899, CSC has offices throughout the United States, Canada, Europe, and the Asia-Pacific region. CSC is a global company capable of doing business wherever our clients are—and we accomplish that by employing experts in every business we serve. Visit cscdbs.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For more information:
Christine Blake
W2 Communications
703-877-8114
CSC@w2comm.com
CSC® News Room

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release

Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release

Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas

Enhertu ® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 09:30:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across three phase 2 trials, including DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02. In DESTINY-PanTumor02, Enhertu demonstrated a confirmed objective response rate (ORR) of 52.3% (95% confidence interval [CI]: 42.6-6

Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 08:00:00 EEST | Press release

The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. The company is one of the leading suppliers of maintenance and modification serv

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye